Mark Evans
Founding Partner & LP Investment Committee Member @ Kindred Capital
London, United Kingdom
Mark Evans is a Series A investor at Kindred Capital in London focused on Retail and Fashion. Mark is currently a Founding Partner and LP and Investment Committee member at Kindred Capital, a European Seed-Stage Venture fund, based in London. He was a General Partner at Balderton Capital/ Benchmark Europe from 2002 through 2015, and an EIR at Benchmark Capital in 1999/2000.He spent the prior 15 years @ Goldman Sachs, where hewas a General Partner and Management Committee member. He studied Economics at both University of Oxford and Queen's University in Canada.
- Total investments:
- 37
- Last investment:
- Lead investor:
- 38%
Last updated:
For AI agents: llms.txt
Industries Mark Evans invests in
Stages Mark Evans invests in
Countries Mark Evans invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Seed
- $1.4M–$8M
- Series A
- $3.2M–$24M
- Series C
- $8M–$68M
Investment Focus
Industry
- Retail 4 (11%)
- Fashion 4 (11%)
- Software 4 (11%)
- E-Commerce 4 (11%)
- Health Care 4 (11%)
Stage
- Series A 6 (16%)
- Seed 5 (14%)
- Series C 5 (14%)
- Funding Round 5 (14%)
- Series D 4 (11%)
Country
- United Kingdom 10 (27%)
- United States 3 (8%)
- The Netherlands 2 (5%)
- Germany 1 (3%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Paddle
|
Paddle develops a Revenue Delivery Platform for B2B SaaS companies that powers growth across acquisition, renewals, and expansion. With Paddle, companies are finally able to transform their revenue delivery infrastructure into a strategic growth lever to respond faster and more precisely to every opportunity. Paddle has 140 talented employeesserving over 2,000 software sellers in 245 countries and territories globally. Backed by investors including FTV Capital, Kindred, Notion, and 83North, Paddle aims to define the next wave of B2B SaaS leaders.It was founded in 2012 and is headquartered in London, England. | $200M / Series D / May 09, 2022 | |
Lyst
|
Lyst is a global fashion search platform used by 70 million shoppers every year. Offering over 4 million fashion products from 11,000 of the world’s leading fashion brands and stores, Lyst brings together the widest inventory in luxury and contemporary fashion online. The company has raised $60 million to date, and is backed by range of all-starinvestors including 14W (Moda Operandi, Reformation), Accel Partners (Facebook, Spotify), Balderton (Yoox Net-A-Porter Group), Draper Esprit, part of the Draper Venture Network (Hotmail, Skype), and the teams behind LVMH, Michael Kors, Oscar de la Renta, and Tory Burch. | $85M / Series D / May 12, 2021 | |
|
Paddle
|
Paddle develops a Revenue Delivery Platform for B2B SaaS companies that powers growth across acquisition, renewals, and expansion. With Paddle, companies are finally able to transform their revenue delivery infrastructure into a strategic growth lever to respond faster and more precisely to every opportunity. Paddle has 140 talented employeesserving over 2,000 software sellers in 245 countries and territories globally. Backed by investors including FTV Capital, Kindred, Notion, and 83North, Paddle aims to define the next wave of B2B SaaS leaders.It was founded in 2012 and is headquartered in London, England. | $68M / Series C / Nov 17, 2020 | |
Ufonia
|
Ufonia is replacing routine patient healthcare interactions with next-generation automated phone calls. | Angel / Oct 03, 2020 | |
Arctoris
|
Arctoris is a platform company headquartered in Oxford, with its US operations based in Boston and its APAC operations based in Singapore. Arctoris developed and operates a unique drug discovery platform powered by advanced robotics and data science combined with an experienced team of biotech & pharma veterans. Arctoris actively pursuesseveral drug discovery programs in oncology and neuro, while also providing access to its platform to select biotech and pharma partners. Arctoris' approach of data-driven drug discovery leads to higher chance of success, and an accelerated progression of programs towards the clinic. | $8M / Seed / Jul 01, 2019 | |
Hubs
|
Hubs, formerly 3D Hubs, is an online platform for custom part manufacturing, providing access to a global network of manufacturing services, including CNC machining, 3D printing, injection molding and sheet metal fabrication. Founded in Amsterdam in 2013, Hubs was acquired by Protolabs in January 2021 and has produced 7 million parts. | $20M / Series C / Mar 26, 2019 | |
|
Paddle
|
Paddle develops a Revenue Delivery Platform for B2B SaaS companies that powers growth across acquisition, renewals, and expansion. With Paddle, companies are finally able to transform their revenue delivery infrastructure into a strategic growth lever to respond faster and more precisely to every opportunity. Paddle has 140 talented employeesserving over 2,000 software sellers in 245 countries and territories globally. Backed by investors including FTV Capital, Kindred, Notion, and 83North, Paddle aims to define the next wave of B2B SaaS leaders.It was founded in 2012 and is headquartered in London, England. | $8M / Series B / Nov 05, 2018 | |
ONI
|
ONI is a pioneer of super-resolution microscopy, making this advanced technology accessible to new generations of researchers. The Nanoimager, the world's first benchtop sized super-resolution microscope, delivers a step change in usability and precision. This, together with our next-generation consumable products will empower academicresearchers, clinicians and scientists to on a path to discovery.The microscope offers easy access to a range of super-resolution techniques including dSTORM and PALM, as well as smFRET, single-particle tracking and confocal.The company's achievements have been recognised by FastTrack100 who named ONI on their 2018 list of 10 Disruptors to Watch and ONI won Best Business Start-up at the 2018 IOP Awards. More and more life science researchers and pharma companies are taking an interest in ONI and it now has customers using its products in leading laboratories across the globe, including the Universities of Oxford, Cambridge and Harvard.ONI has a restless enthusiasm to make the world a better place. Our ambition is to bring super-resolution fluorescence imaging to a new community of researchers and we are removing barriers to make science more effective, accessible and affordable. Our vision is to accelerate scientific discovery and fight disease by enabling everyone to visualize, understand and share the microscopic details of life. | $24M / Series A / Jul 13, 2018 | |
|
Paddle
|
Paddle develops a Revenue Delivery Platform for B2B SaaS companies that powers growth across acquisition, renewals, and expansion. With Paddle, companies are finally able to transform their revenue delivery infrastructure into a strategic growth lever to respond faster and more precisely to every opportunity. Paddle has 140 talented employeesserving over 2,000 software sellers in 245 countries and territories globally. Backed by investors including FTV Capital, Kindred, Notion, and 83North, Paddle aims to define the next wave of B2B SaaS leaders.It was founded in 2012 and is headquartered in London, England. | $12.5M / Series B / Dec 14, 2017 | |
myTomorrows
|
myTomorrows is an independent, globally operating organization based in the Netherlands. We provide patients with unmet medical needs, and their doctors, information about treatment options worldwide and facilitate access to medicines in development. Our goal is to ensure that patients and doctors don’t miss out on treatment options due to lack ofinformation, understanding and administrative hurdles. Working together with medicine manufacturers to devise and execute strategies for early access, we strive to make it easier for doctors and their patients who ran out of viable treatment options to find, get information about and access to medicines in development. myTomorrows has developed a Knowledge Base to combine vast amounts of medical and clinical data to present an actionable overview of the full clinical development pipeline. | $10.6M / Venture - Series Unknown / Jan 09, 2017 | |
| See all 37 investments → | |||
Co-Investors
About Kindred Capital
Kindred is an early stage venture capital fund based in London that practices equitable venture. Kindred aligns ambitions and achievements with the portfolio. In structure and in spirit. Every single founder that the company backs will become a co-owner of the fund.
Kindred Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Chrysanthos Chrysanthou
Partner
|
|||
Leila Zegna
Founding Partner
|
|||
Andrew Baldwin
Finance & Operations Lead
|
|||
John Cassidy
Partner
|
|||
Karen Swain
CFO
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Mark Evans invest in?
Mark Evans invests primarily in Retail, Fashion and Software startups, most often at Series A and Seed stage. Most of the 37 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Mark Evans's check size?
Mark Evans typically joins rounds of $1.4M–$8M at Seed, $3.2M–$24M at Series A and $8M–$68M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Mark Evans participates in.
How do I contact Mark Evans?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Mark Evans last invest?
The most recent investment recorded for Mark Evans closed in May 2022. Shizune tracks 37 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
